抗艾美赛珠单抗抗体降低药物疗效的详细分析:一例血友病A患者血浆样本研究
本文报告一例FVIII抑制物阳性的成人血友病A患者,因反复出血和活化部分凝血活酶时间延长而停用艾美赛珠单抗。利用残余血浆样本检测艾美赛珠单抗浓度、抗药抗体滴度及中和活性,发现抗药抗体识别艾美赛珠单抗的抗FIXa和抗FX Fab臂,并具有中和活性及加速药物清除的潜力,导致疗效下降。
要点
- 抗药抗体可识别艾美赛珠单抗的抗FIXa和抗FX Fab臂而非Fc区。
- 抗药抗体具有中和活性并可能加速艾美赛珠单抗清除。
- 抗药抗体出现与艾美赛珠单抗浓度下降及疗效降低相关。
核心结论
- 具有艾美赛珠单抗中和活性及加速清除潜力的抗药抗体出现,降低了艾美赛珠单抗的疗效。
研究设计与样本
- 病例研究,使用一例FVIII抑制物阳性成人血友病A患者的残余血浆样本。
主要发现
- 第31周艾美赛珠单抗浓度为15.0 μg/ml,抗药抗体检测为阳性。
- 艾美赛珠单抗浓度持续下降直至第49周停药点,第50周后浓度低于定量下限。
- 抗药抗体滴度自第31周短暂升高,甚至超过第49周停药点,后逐渐下降至第93周末次采样点。
- 停药后检测到针对艾美赛珠单抗的中和活性。
- 表位分析显示抗药抗体识别艾美赛珠单抗的抗FIXa和抗FX Fab臂,而不识别Fc区。
临床怎么用
- 对艾美赛珠单抗治疗中出现反复出血或活化部分凝血活酶时间延长的患者,应考虑检测抗药抗体。
局限性
- 证据来自单一病例的残余血浆样本分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emicizumab is a humanized bispecific monoclonal antibody that bridges activated factor IX (FIXa) and factor X (FX) to mimic the function of factor VIII (FVIII). It suppresses the bleeding tendency in hemophilia A patients with or without FVIII inhibitors. A case of an adult FVIII inhibitor-positive hemophilia A patient in whom treatment with emicizumab was discontinued owing to the repeated bleeding events and prolonged activated partial thromboplastin time. OBJECTIVE: To analyze the mechanisms of decreased efficacy of emicizumab. METHODS: Residual plasma samples were used to measure the following: emicizumab concentration in plasma, measured by enzyme-linked immunosorbent assay; titer of anti-drug antibody (ADA) against emicizumab, measured by electrochemiluminescence; and neutralizing activity against emicizumab, measured by Bethesda method modified by using emicizumab-spiked FVIII-deficient plasma. RESULTS: At week 31, emicizumab concentration was 15.0 μg/ml, and ADAs were measured as positive. Emicizumab concentration continued to decrease until emicizumab discontinuation point at week 49, and after week 50, emicizumab concentrations were below the limitation of quantification. The ADA titer increased transiently from week 31, even past the emicizumab discontinuation point at week 49. The ADA titer then gradually decreased until the last sampling point at week 93. Neutralizing activity against emicizumab was detected after emicizumab discontinuation. Epitope analysis showed that the ADAs recognize the anti-FIXa and anti-FX Fab arms of emicizumab, but not the Fc region. CONCLUSION: The appearance of ADAs with emicizumab-neutralizing activity and potential to accelerate emicizumab clearance decreased the efficacy of emicizumab.
引用
- Kaneda M, Kawasaki R, Matsumoto N, et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost. 2021. PMID: 34418287. doi:10.1111/jth.15506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。